Gland Pharma MD, chairman, board of directors and AGM

Mutual fund votes, meeting of 25 Aug 2026, 13 fund houses so far (houses' deadline to file 15 Oct 2026)

Each resolution counts the houses whose vote was matched to it; the rest are listed last.

• To receive, consider and adopt the audited Standalone Financial Statements of the Company for the Financial Year ended 31st March, 2026 including the Audited Balance Sheet as at 31st March, 2026; the Statement of Profit and Loss, Statement of changes in Equity and the Statement of Cash Flows for the year ended on that date along with the Schedules and Notes thereon together with the Reports of the Board of Directors and Auditors thereon.MoreLess

  12 for0 against
• To receive, consider and adopt the audited Consolidated Financial Statements of the Company for the Financial Year ended 31st March, 2026 including the Audited Consolidated Balance Sheet as at 31st March, 2026; the Consolidated Statement of Profit and Loss, Consolidated Statement of changes in Equity and the Consolidated Statement of Cash Flows for the year ended on that date along with the Schedules and Notes thereto, together with the Report of the Auditors thereonMoreLess

  12 for0 against
• To declare the final dividend on equity shares for the financial year ended 31st March 2026.

  13 for0 against
• To reappoint Mr. Wenjie Zhang as a Director, liable to retire by rotation and being eligible offers himself for reappointment.

  ›Against Angel One Mutual Fund, DSP Mutual Fund, Edelweiss Mutual Fund, HSBC Mutual Fund, Jio BlackRock Mutual Fund, LIC Mutual Fund, Mahindra Manulife Mutual Fund, Navi Mutual Fund, PGIM India Mutual Fund, Sundaram Mutual Fund

  • Angel One Mutual Fund, LIC Mutual FundGovernance Concern: Low attendance at board meetings.
  • DSP Mutual Fund, Jio BlackRock Mutual Fund, Mahindra Manulife Mutual Fund, Sundaram Mutual FundWenjie Zhang, 59, is Executive President and Co-CEO, Innovative Medicines division - Fosun Pharma. He has been on the board of the company since August 2024. He attended three of the six (50%) board meetings held in FY26 and five of ten (50%) since his appointment to the board. We expect directors to attend all board meetings and at a minimum, 75% board meetings over a three-year period prior to their reappointment. Given his low board meeting attendance, we are unable to support the resolution.
  • Edelweiss Mutual Fund, Navi Mutual Fund, PGIM India Mutual FundCompliant with law. Governance Concern: Low attendance at board meetings.
  • HSBC Mutual FundA vote AGAINST the following nominee is warranted because: • The board is chaired by an executive director, and the board is not at least one-half independent (after our re-classification), and Wei Huang and Wenjie Zhang are non-independent director nominees. • Wenjie Zhang failed to attend at least 75 percent of board and key committee meetings in the most recent fiscal year, without a satisfactory explanation.

  3 for10 against
• To reappoint Ms. Wei Huang as a Director, liable to retire by rotation and being eligible offers herself for reappointment

  ›Against Angel One Mutual Fund, DSP Mutual Fund, Edelweiss Mutual Fund, HSBC Mutual Fund, Jio BlackRock Mutual Fund, LIC Mutual Fund, Mahindra Manulife Mutual Fund, Navi Mutual Fund, PGIM India Mutual Fund, Sundaram Mutual Fund

  • Angel One Mutual FundGovernance Concern: Low attendance at board meetings; Proposed appointee is Nomination and Remuneration Committee member and the Company’s remuneration practice is skewed in favour of an Independent Director.
  • DSP Mutual Fund, Jio BlackRock Mutual Fund, Mahindra Manulife Mutual Fund, Sundaram Mutual FundMs. Wei Huang, 58, is President, Shanghai Henlius Biotech Inc. She has been on the board since November 2024. She attended three of the six (50%) board meetings held in FY26 and four of eight (50%) since her appointment to the board. We expect directors to attend all board meetings and at a minimum, 75% board meetings over a three-year period prior to their reappointment. Given her low board meeting attendance, we are unable to support the resolution.
  • Edelweiss Mutual Fund, Navi Mutual FundCompliant with law. Governance Concern: Low attendance at board meetings; Proposed appointee is NRC member and the Company’s remuneration practice is skewed in favour of an ID.
  • HSBC Mutual FundA vote AGAINST the following nominee is warranted because: • The board is chaired by an executive director, and the board is not at least one-half independent (after our re-classification), and Wei Huang and Wenjie Zhang are non-independent director nominees. • Wei Huang failed to attend at least 75 percent of board and key committee meetings in the most recent fiscal year, without a satisfactory explanation.
  • LIC Mutual FundGovernance Concern: Low attendance at board meetings; Proposed appointee is NRC member and the Company s remuneration practice is skewed in favour of an ID.
  • PGIM India Mutual FundCompliant with law. Governance Concern: Low attendance at board meetings; Proposed appointee is NRC member and the Company s remuneration practice is skewed in favour of an ID.

  3 for10 against

Mutual fund votes, meeting of 18 Jul 2026, 11 fund houses so far (houses' deadline to file 15 Oct 2026)

• To reappoint Mr. Udo Jahannes Vetter, DIN: 00707474 as an Independent Director of the company.

  ›Against Angel One Mutual Fund, DSP Mutual Fund, Edelweiss Mutual Fund, Jio BlackRock Mutual Fund, LIC Mutual Fund, Mahindra Manulife Mutual Fund, Navi Mutual Fund, Sundaram Mutual Fund, Tata Mutual Fund

  • Angel One Mutual FundGovernance Concern: Prolonged association with the Company. No cooling-off period served from his transition/appointment as Non-Executive Director to Independent Director. Remuneration Practice appears to be skewed where proposed Director is a Chairman of Nomination & Remuneration Committee.
  • DSP Mutual Fund, Jio BlackRock Mutual Fund, Sundaram Mutual Fund, Tata Mutual FundUdo Johannes Vetter, 72, currently serves as Chairperson of the ITM Group, Germany. He is the Chairperson of the Vetter Pharma Group. He was Non-Executive Non-Independent Director on the board from 1996. Udo Johannes Vetter along with his family and associates had been shareholders in the company since 1996 until Fosun Pharma’s acquisition of majority stake in the company in October 2017. Following this, he became a nominee director of the Penmetsa family, erstwhile promoters of the company. Subsequent to Gland Pharma’s IPO in November 2020, he ceased to be a nominee of the erstwhile promoters as their shareholding fell from ~20% to ~11%. He was appointed as Independent Director on the board on 21 July 2021. The company seeks his reappointment as Independent Director for five years from 21 July 2026 and for his continuation on the board after attaining 75 years of age on 21 July 2031. We consider his overall tenure from his date of association with the new promoters, i.e., October 2017. He attended all six board meetings held in FY26. However, he will cross ten years of association with the company (Since Fosun Pharma’s acquisition of the company) during the proposed tenure. Therefore, we do not support his reappointment as Independent Director. The company must consider appointing him as Non-executive Non-Independent Director.
  • Edelweiss Mutual Fund, LIC Mutual Fund, Navi Mutual FundCompliant with law. Governance Concern: Prolonged association with the Company. No cooling-off period served from his transition/appointment as NED to ID. Remuneration Practice appears to be skewed where proposed Director is a Chairman of NRC.
  • Mahindra Manulife Mutual FundGovernance Concern: Prolonged association with the Company. No cooling-off period served from his transition/appointment as NED to ID. He was Non-Executive Non-Independent Director on the board from 1996. Udo Johannes Vetter along with his family and associates had been shareholders in the company since 1996 until Fosun Pharma’s acquisition of majority stake in the company in October 2017. Following this, he became a nominee director of the Penmetsa family, erstwhile promoters of the company. Subsequent to Gland Pharma’s IPO in November 2020, he ceased to be a nominee of the erstwhile promoters as their shareholding fell from ~20% to ~11%. He was appointed as Independent Director on the board on 21 July 2021. While there are no concerns over the profile or time commitments, we believe his long-tenured association with the company needs to be considered in its entirety and accordingly he should be designated as non-independent director.

  2 for9 against
• To consider Commission on profits as remuneration to Mr. Udo Jahannes Vetter, DIN: 00707474.

  ›Against Angel One Mutual Fund, Edelweiss Mutual Fund, LIC Mutual Fund, Navi Mutual Fund

  • Angel One Mutual FundGovernance concern: Interconnect with Resolution #1. Excessive remuneration proposed to Independent Directors without adequate justification and within a short span of time.
  • Edelweiss Mutual Fund, LIC Mutual Fund, Navi Mutual FundCompliant with law. Governance concern: Interconnect with Resolution #1. Excessive remuneration proposed to IDs without adequate justification and within a short span of time.

  7 for4 against
• To appoint Mr. William Robert Keller, DIN: 11593622 as an Independent Director of the Company.

  ›Against Angel One Mutual Fund, Edelweiss Mutual Fund, LIC Mutual Fund, Navi Mutual Fund

  • Angel One Mutual FundPrior Approval not sought for appointment / continuation of Director above 75 years of age.
  • Edelweiss Mutual Fund, LIC Mutual Fund, Navi Mutual FundNo concern on the merits of the appointee. Non-Compliant under Regulation 17(1A) of SEBI LODR, 2015: Prior Approval not sought for appointment / continuation of Director above 75 years of age.

  7 for4 against
• To consider Commission on profits as remuneration to Mr. William Robert Keller, DIN: 11593622.

  ›Against Angel One Mutual Fund, Edelweiss Mutual Fund, LIC Mutual Fund, Navi Mutual Fund

  • Angel One Mutual FundInterconnect with Resolution #3. Governance Concern: Excessive remuneration proposed to Independent Director without adequate justification.
  • Edelweiss Mutual Fund, LIC Mutual Fund, Navi Mutual FundCompliant with law. Non-Compliant under Regulation 17(1A) of SEBI LODR, 2015: Interconnect with Resolution #3. Governance Concern: Excessive remuneration proposed to ID without adequate justification.

  7 for4 against
• To consider revision of Commission on profits as remuneration to Mr. Essaji Goolam Vahanvati, DIN: 00157299, Independent Director.

  ›Against Angel One Mutual Fund, Edelweiss Mutual Fund, LIC Mutual Fund, Navi Mutual Fund

  • Angel One Mutual FundGovernance Concern: Excessive remuneration proposed to Independent Directors without adequate justification and within a short span of time. Remuneration Practice appears to be skewed where proposed Director is Member of Nomination & Remuneration Committee.
  • Edelweiss Mutual Fund, LIC Mutual Fund, Navi Mutual FundCompliant with law. Governance Concern: Excessive remuneration proposed to IDs without adequate justification and within a short span of time. Remuneration Practice appears to be skewed where proposed Director is Member of NRC.

  7 for4 against

The board is made up as the listing rules require

Yes

The board has a regular chairperson

Yes

The company has a risk management committee

Yes

The chair is related to the managing director

No

The filing has a part on fines and penalties

No

The filing has a part on tax disputes

No

There was a cyber security incident in the quarter

No

The company's own answers in its filing.